Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. director Wanda M. Austin received a stock-based compensation award. She acquired 665 shares of Amgen common stock on May 19, 2026 through a grant classified as a “grant, award, or other acquisition,” not an open-market purchase.
The shares came from Restricted Stock Units granted under Amgen’s 2009 Director Incentive Program within the company’s equity incentive plan. According to the footnote, these RSUs vested immediately and are paid in common stock on a one-to-one basis, with an option for the director to defer receipt. Following this grant, Austin directly holds 8,018 shares of Amgen common stock.
Amgen Inc. reported the results of its annual stockholder meeting held on May 19, 2026. All 12 director nominees were elected, each receiving over 390 million votes in favor with substantial margins over votes against.
Stockholders approved the advisory vote on executive compensation, with 399,315,381 votes for and 11,987,682 against, and ratified Ernst & Young LLP as independent registered public accountants for the 2026 fiscal year with 447,904,443 votes for. A stockholder proposal to require an independent board chairman did not pass, receiving 72,902,413 votes for and 338,465,655 votes against.
Amgen Inc. announced a planned chief financial officer transition. Peter H. Griffith, executive vice president and CFO since 2020, will retire from the CFO role effective August 31, 2026 and remain as an executive vice president until his departure in January 2027.
The board approved hiring Thomas Dittrich, age 62, as executive vice president effective July 1, 2026, and he will become executive vice president and CFO on September 1, 2026. His employment offer includes an annual base salary of CHF 1,070,000, eligibility for a target bonus equal to 100% of base salary, and fiscal 2026 long-term equity incentives with a target value of CHF 4,500,000.
To replace compensation forfeited at his current employer, Dittrich will receive a one-time RSU award valued at CHF 4,700,000 and a one-time Swiss cash bonus of CHF 4,000,000, plus a separate two-year retention bonus of CHF 5,800,000. His package also includes relocation benefits, an additional relocation allowance, and a severance agreement providing two times salary and target bonus if terminated by Amgen without cause within two years of his hire date.
Amgen Inc. shareholder Capital World Investors reports beneficial ownership of 29,596,119 shares of Common Stock, equal to 5.5% of the 539,067,675 shares outstanding disclosed in the filing. The filing shows 29,296,381 shares with sole voting power and 29,596,119 shares with sole dispositive power.
Amgen VP, Finance & CAO Matthew C. Busch reported a small tax-related share disposition. On the transaction date, 41 shares of Amgen common stock were withheld at $331.11 per share to cover tax obligations related to equity compensation. After this non-market tax-withholding event, Busch directly held 4,344 Amgen shares, which include 39 Dividend Equivalents tied to unvested Restricted Stock Units under the company’s equity incentive plan.
Amgen Inc. executive Esteban Santos reported routine share updates related to compensation and plan holdings. On May 7, 2026, 522 shares of Amgen common stock were disposed of in a tax-withholding transaction at $331.11 per share to satisfy exercise price or tax liabilities. After this, he directly owned 82,847 common shares. He also reported 909.9906 shares held indirectly through a 401K Plan. The reported holdings include 327 Dividend Equivalents credited to unvested Restricted Stock Units, which will be paid in common shares on a one-to-one basis according to their vesting schedule.
Amgen Inc. executive David M. Reese reported a routine tax-related share disposition. On 2026-05-07, 556 shares of Amgen common stock were withheld at $331.11 per share to satisfy tax obligations associated with equity compensation. After this withholding, he directly holds 42,256 shares of Amgen common stock. A footnote also notes 350 Dividend Equivalents tied to unvested Restricted Stock Units that will pay out in shares as they vest.
Amgen Inc. senior vice president of human resources Derek Miller reported a small tax-related share disposition. On May 7, 2026, 151 shares of Amgen common stock were withheld at $331.11 per share to cover tax obligations, a non-market transaction. After this event, Miller directly holds 12,444 shares, which include 99 dividend equivalents tied to unvested restricted stock units that will settle in shares as they vest.
Amgen Inc. senior vice president Rachna Khosla had 93 shares of common stock withheld on May 7, 2026 to cover tax obligations. The shares were valued at $331.11 each. After this tax-withholding disposition, she directly holds 8,394 shares of Amgen common stock.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported routine share activity involving Amgen common stock. The filing shows a tax-withholding disposition of 88 shares of common stock at $331.11 per share, used to cover tax obligations rather than representing an open-market sale. After this transaction, she holds 7,330 Amgen shares directly. The filing also notes an indirect holding of 106.1864 shares in a 401(k) plan, which includes 58 Dividend Equivalents tied to unvested Restricted Stock Units that will be paid out in shares as they vest.